ProCE Banner Activity

Phase I/II TRANSCEND CLL 004: Updated Results of Lisocabtagene Maraleucel in Patients With Relapsed/Refractory CLL or SLL

Slideset Download
Conference Coverage
Lisocabtagene maraleucel showed manageable toxicity and clinical activity in heavily pretreated patients with high-risk CLL/SLL who failed prior ibrutinib.

Released: December 19, 2019

Expiration: December 17, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company